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Abstract
Ghrelin is an endogenous regulator of energy homeostasis synthesized by the stomach to stimulate appetite and positive
energy balance. Similarly, the endocannabinoid system is part of our internal machinery controlling food intake and energy
expenditure. Both peripheral and central mechanisms regulate CB1-mediated control of food intake and a functional
relationship between hypothalamic ghrelin and cannabinoid CB1 receptor has been proposed. First of all, we investigated
brain ghrelin actions on food intake in rats with different metabolic status (negative or equilibrate energy balance).
Secondly, we tested a sub-anxiogenic ultra-low dose of the CB1 antagonist SR141716A (Rimonabant) and the peripheral-
acting CB1 antagonist LH-21 on ghrelin orexigenic actions. We found that: 1) central administration of ghrelin promotes
food intake in free feeding animals but not in 24 h food-deprived or chronically food-restricted animals; 2) an ultra-low dose
of SR141716A (a subthreshold dose 75 folds lower than the EC50 for induction of anxiety) completely counteracts the
orexigenic actions of central ghrelin in free feeding animals; 3) the peripheral-restricted CB1 antagonist LH-21 blocks
ghrelin-induced hyperphagia in free feeding animals. Our study highlights the importance of the animals metabolic status
for the effectiveness of ghrelin in promoting feeding, and suggests that the peripheral endocannabinoid system may
interact with ghrelins signal in the control of food intake under equilibrate energy balance conditions.
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Introduction
Ghrelin is a potent anabolic molecule with orexigenic and
adipogenic actions. This hormone is produced in the periphery,
mainly by the stomach but also by lower parts of the
gastrointestinal tract [1,2,3]. The peripherally-produced ghrelin
reaches the central nervous system via the activation of the vagus
nerve. Within the central nervous system, ghrelin activates specific
hypothalamic areas connecting with the orexigens neuropeptide Y,
orexin, and Agouti-related peptide [4,5] and regulates growth
hormone (GH) secretion and energy homeostasis [6]. Ghrelin
receptor (growth hormone secretagogue receptor, GHS-R1a) is
located in the hypothalamus, nodose ganglia and gastrointestinal
tract and its activation reduces energy expenditure, stimulates food
intake and promotes gluconeogenesis and adipose tissue deposition
[2,7,8]. In addition, feeding status appears to determine plasma
ghrelin levels in humans [1]. However, the orexigenic actions of
ghrelin administration are mainly known in the context of an
equilibrated energetic balance but little is known about the role of
this hormone in different feeding status where the energy intake is
not equal to the energy expenditure.
Similar to ghrelin, the endogenous cannabinoid system (ECS)
plays a major role in feeding control, energy homeostasis and
metabolism [9,10,11,12]. Both peripheral and central mechanisms
for the ECS-mediated control of feeding have been described. The
ECS controls food intake by a complex network of interactions
with a wide variety of peptides or hormones, including orexin A-
hypocretin 1 [13,14,15], cholecystokinin [16], oxytocin [17], leptin
[18], and the melanocortin [19,20] and opioid [21,22] systems.
Additionally, a functional relationship between central ghrelin and
CB1 receptors has also been described, suggesting that the
interplay between both systems may take place in the hypotha-
lamic paraventricular nucleus [23,24]. However, whether ECS
and ghrelin may interplay also at a peripheral level is unknown.
Blockade of the CB1 receptors emerged as a potential valuable
tool for the treatment of diet-induced obesity since chronic
pharmacological blockade of CB1 receptors decreases food intake
and body weight and improves lipid metabolism not only in
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animal models of obesity but also in humans [25,26]. According to
this beneficial profile, the CB1 antagonist SR141716A (Rimona-
bant, AcompliaH) was translated into therapy for humans [27].
Unfortunately, blockade of CB1 receptors was found to decrease
food intake but also to induce central side effects such as
depression [28] and, as a consequence, the compound was finally
withdrawn from the market due to important psychiatric side
effects (http://www.ema.europa.eu/humandocs/Humans/
EPAR/acomplia/acomplia.htm). However, a better scientific
understanding of the ECS distribution, mode of action and
interplay with other systems may led us to rescue the positive
effects of CB1 antagonism on food intake and metabolism
regulation avoiding the limiting side central effects [29]. It is
important to stress that the potency of SR141716A for inducing
satiety in animals is similar to that for inducing anxiety ([30]; and
this paper). In this regard, there is an increasing interest for
developing new CB1 antagonist acting mainly peripherally [29].
The CB1 receptor distribution in the periphery include several
tissues involved in metabolic actions such as liver, gastrointestinal
tract, pancreas, or adipose tissue [31,32,33,34]. Previous investi-
gations allowed the identification of peripheral mechanisms for the
ECS in the regulation of feeding behavior [35]. Systemic
administration of low doses of SR141716A enhances c-fos
expression in brainstem areas receiving vagal inputs as indicative
of peripheral nervous system activation [16]. This c-fos expression
in brainsteam areas was attenuated after higher doses of
SR141716A, indicating a dose-dependent peripheral versus
central actions of SR141716A [16]. In the last years, peripheral-
restricted CB1 antagonists have been developed and tested for
feeding inhibition [36,37].
Because peripheral CB1 receptors may control appetite while
no inducing anxiety [36], we further investigated whether
peripheral-acting CB1 receptor antagonists may modulate other
signals controlling appetite such as ghrelin. In this study we aim to
determine the role of central ghrelin on food intake in rats under
different metabolic status and investigate in vivo the functional
interaction between ghrelin and the ECS, with emphasis in the
role of peripheral CB1 receptors modulating the orexigenic signal
of ghrelin. Our results provide a new perspective in the interaction
between ghrelin and CB1 receptors and suggest that therapies
using new peripheral-restricted CB1 antagonist might be effica-
cious for the treatment of obesity when ghrelin-inducing food
intake signal is overactivated.
Materials and Methods
Ethic statement
The protocols for animal care and use were approved by the
appropriate Committee of the Ethics of Animal Experiments of
the Complutense University. Furthermore, all experimental
procedures were carried out according to the European Commu-
nities Council Directive of 22 July 2003 (2003/65/CE) and
current Spanish regulations of animal research (Real Decreto
1201/2005, BOE 21–10–2005). All efforts were made in order to
minimize the number and suffering of the animals used.
Animals
Experimental subjects were a total of 171 adult male Wistar rats
(Harlan Ibe´rica, Madrid, Spain) weighting approximately 250–
270 g on the beginning of experiments and housed individually.
The animals were acclimated to the facility and handled before
any experiment. Rats were kept at constant room temperature
(2261uC) and relative humidity (5262%) in a 12 h light/dark
cycle (lights on at 7:00 am) and had free access to water. The
majority of the experiments were started around 11 am. Free-feeding
animals had free access to standard pellets of food; fasted rats were
totally deprived for food during 24 h before the experiment; and
chronic food-restricted rats were limited daily for food intake until
body weights reached 80% of free-feeding values (20–25 days).
When body weights reached the target value, the amount of food
was adjusted daily to maintain a constant body weight. Standard
pellets were presented to the rats and food consumption was
evaluated at different time points after the beginning of food
presentation. The nutritional composition of the regular diet for
rats was 16.10% crude protein, 3.10% crude fat, 5.10% crude ash,
3.90% crude fibre, and a pre-mixture of vitamins and minerals,
dicalcium phosphate and calcium carbonate. Body weight and
water intake were also evaluated before and after food tests. The
number of animals per group was 9 rats for each treatment in each
condition.
Surgery
Rats were anesthetized with equithesin (3 mg/kg) and unilat-
erally implanted with a stainless-steel guide cannula (22-G,
Nessler, Spain) for intracerebroventricular (i.c.v.) injections.
Cannula was aimed at the right or left brain lateral ventricle
and stereotaxically implanted according to coordinates determined
from the rat brain atlas of Paxinos and Watson (1998) [38]
(20.92 mm antero-posterior; 61.4 mm lateral to bregma, and
2.8 mm below the skull surface). The injector extended 1 mm
beyond the end of the guide cannula. Animals were allowed 9 days
post-operative recovery prior to any experimental manipulation.
Extensive details on the methods have been published elsewhere
[35].
Drugs and treatments
Ghrelin (Tocris, Madrid, Spain) was dissolved in saline (99%)
and dimethylsulfoxide (DMSO) (1%) and was administrated i.c.v.
in brain lateral ventricle (0.25, 0.5 or 1 mg in 5 ml during 30 s)
following a between-subject design with repeated measures at
different time points. To ensure complete dispersal of the
treatment we kept the injector in situ for additional 30 s.
SR141716A (N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichloro-
phenyl)-4-methylpyrazole-3-carboxamide or Rimonabant) was
kindly provided by Sanofi Recherche (Montpellier, France) and
LH-21 [5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-
1,2,4-triazole] was synthesized in our laboratory as described
before [39]. Both SR141716A and LH-21 were suspended in a
vehicle containing Tween 80 (1%) and saline (99%) and
administered by intraperitoneal injection in a volume of 1 ml/kg
prior to the i.c.v. injection of ghrelin or vehicle.
Rats received three habituation i.c.v. injections and two
intraperitoneal injections (saline) before any treatment.
Statistical analysis
Statistical analyses were performed using SPSS statistical
package version 11.0 to Windows or GraphPad Prism (version
5.0) software. A three-way analysis of variance (ANOVA) was
performed with three variables: metabolic status (between subjects)
x ghrelin dose (between subjects) x time (within subjects). The two-
way ANOVAs were performed followed by a Bonferroni post hoc
test. All data are presented as mean6 standard errors of the mean
and P,0.05 was considered statistically significant.
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Results
Effect of i.c.v. ghrelin administration on food intake in
rats with different metabolic status
We tested whether treatment with ghrelin (0, 0.25, 0.5 or 1 mg
i.c.v.) increased feeding in animals under different metabolic
status: animals ad lib fed (free feeding animals), food-deprived for
24 hours (fasted), and chronic food-restricted rats (n = 9 per group)
at different time points (60 min and 120 min) post treatment. A 3-
way ANOVA (metabolic status x ghrelin dose x time) revealed no
overall interaction among the three factors (F(6,96) = 0.44,
P = 0.85). However, the test of between-subject effects revealed
an interaction between the metabolic status and the dose of ghrelin
(F(6,96) = 7,15, P = 0.0001), being ghrelin treatment effective in free
feeding animals but not in fasted or chronically deprived animals.
The test of within-subject contrast revealed no effect of time and
ghrelin doses (F(3,96) = 0.28, P= 0.84) but an overall interaction
between time and metabolic status (F(2,96) = 10,79, P = 0.0001),
being the time after food presentation more influencing in those
conditions where the animals were restricted for food. A
comparison among vehicle-injected rats in each condition using
two-way ANOVA revealed an interaction between metabolic
status and time (F(2,24) = 5.45, P= 0.001), and main effects of time
(F(1,24) = 21.23, P= 0.0001), and metabolic status (F(2,24) = 191.4,
P,0.0001). A Bonferroni post hoc test indicated significant
differences among the control groups in each metabolic condition,
consuming more food the chronically food-restricted rats, follow-
ing by the fasted group and free feeding rats, respectively.
A detailed analysis of the free feeding condition using a two-way
ANOVA revealed a main effect of ghrelin dose (F(3,70) = 154.4,
P,0.0001) and main effect of time (F(1,70) = 52,9, P,0.0001). The
interaction between factors (dose x time) was found in the limit of
significance (F(3,70) = 2.67, P= 0.05). Post hoc analysis showed
significant differences on food intake after ghrelin treatment at
doses of 0.25 mg (P,0.001), 0.5 mg (P,0.001) and 1.0 mg
(P,0.001) 60 min and 120 min after food presentation (Fig. 1).
No changes in water intake were found in any group tested (data
not shown).
EC50 of a dose-response curve of SR141716A on food
intake and anxiety
We calculated the maximal effective concentration (EC50) of the
CB1 antagonist SR141716A on food intake and anxiety (Fig. 2) by
re-analysis of previous data published in [30]. The dose-response
curves of SR141716A follow an inverted pattern for feeding and
anxiety behaviors, being the EC50 for both conditions 2.2 mg/kg
and 2.3 mg/kg, respectively. Taken these data into account, we
choose an ultra-low SR141716A dose of 0.03 mg/kg (75 folds
lower than the EC50) for our behavioral studies to test the effect of
a subthreshold and subanorectic dose of this CB1 antagonist on
ghrelin-induced hyperfagia. Therefore, this dose of SR141716A
has nule effects on food inhibition and induction of anxiety (Fig. 2).
Previous investigations provided evidence for a dose-dependent
effect of SR141716A, being low doses effective for peripheral
activation whereas highest doses clearly act at central level [16].
Consequently, the ultra-low dose of SR141716A chosen in this
study allowed us to test the interaction between ghrelin and CB1
receptors at a peripheral level, as done elsewhere (Crespo I. et al.,
2008).
An ultra-low dose of SR141716A and the peripheral CB1
antagonist LH-21 both counteract ghrelin-induced
orexigenic actions in free feeding animals
Since ghrelin has orexigenic activity only in free feeding animals
we choose this condition to test the effect of a subthreshold dose of
SR141716A on ghrelin-induced hyperphagia (Fig. 3A). Free
feeding animals were pre-treated with an ultra-low dose of
SR141716A (0.03 mg/kg, i.p.) 10 min before the i.c.v. injection
of the maximal ghrelin effective dose (0.5 mg) inducing feeding.
SR141716A dose was selected based on its Ki for feeding and
anxiety behaviors ([13]; and this paper). A two-way ANOVA
revealed no interaction (within factors time and treatment
F(3,66) = 0.12), no effect of time (F(1,66) = 2.64), but there was an
overall effect of treatment (F(3,66) = 14.90). The post hoc analysis
showed that ghrelin increases feeding compared with vehicle at
60 min (P,0.01) and 120 min post-treatment (P,0.001). Pre-
treatment with the non-anorectic dose of SR141716A counteract-
ed the orexigenic effects of ghrelin 60 min (P,0.01) and 120 min
(P,0.001) post- administration. As expected, the ultra-low dose of
0.03 mg/kg of SR141716A produced no significant differences on
food intake versus vehicle-treated animals (P.0.05) (Fig. 3A). No
change was found either on body weight or water intake in those
animals (data not shown).
Additionally, free feeding animals were pretreated with systemic
injections of the peripheral CB1 antagonist LH-21 (3.0 mg/kg,
i.p.) 15 min before an i.c.v. injection of ghrelin (0.5 mg, i.c.v.)
(Fig. 3B). A two-way ANOVA revealed no interaction
(F(3,37) = 0.36) but an overall effect of treatment (F(3,37) = 12.26)
and time (F(1,37) = 11.43). The post hoc test indicate that ghrelin
treatment increases feeding at 60 min (P,0.01) and 120 min post-
treatment (P,0.001) compared with vehicle-injected animals. LH-
21 pretreatment blocked the orexigenic effects of ghrelin in free
feeding animals 60 min (P,0.01) and 120 min (P,0.001) after
injection, and produced no effect on food intake in vehicle-treated
animals (P.0.05, n.s.) (Fig. 3B).
Discussion
The main findings of this study are: a) ghrelin-induced
orexigenic effects depends on the metabolic status of the animal,
being effective in free feeding conditions but having no effect in
animals under negative energy balance conditions such as fasted or
chronically food-restricted rats; b) blockade of CB1 receptors at
extremely low doses (not centrally acting) or with peripheral-
restricted CB1 antagonists is able to counteract the hyperphagic
effect of central ghrelin administration in free feeding animals.
We observed that orexigenic effects of i.c.v. ghrelin administra-
tion are only manifested under equilibrate energy balance
conditions (free feeding) being ghrelin ineffective in animals with
negative energy balance (fasted or chronically food-restricted
animals). The increase in food intake after central ghrelin
administration occurs rapidly at the first 60 minutes, according
to the physiological role of this peptide hormone in meal initiation
in humans [40,41]. Feeding status appears to determine plasma
ghrelin levels in humans [1]. It is known that total ghrelin levels
increase after fasting and are suppressed within minutes by
refeeding or enteral nutrient administration [41,42,43]. Specifi-
cally, plasma ghrelin levels increase by 31% after 12 h fasting and
they are reduced by 22% immediately after feeding [1]. Therefore,
plasma ghrelin levels are upregulated under negative energy
balance conditions including starvation, whereas they are down-
regulated under conditions of positive energy balance [42,43,44].
In line with the aforementioned studies, the lack of ghrelin
administration effect in feeding behaviour found in fasted or
Peripheral CB1 Antagonism on Ghrelin Actions
PLOS ONE | www.plosone.org 3 April 2013 | Volume 8 | Issue 4 | e60918
chronically food-restricted animals in this study might be
explained as the result of a ceiling effect caused by high ghrelin
levels during these negative energy balance’s states. Indeed,
plasma ghelin-like immunoreactivity levels were markedly elevated
in patients with anorexia nervosa and negatively correlated with
body mass indexes [1]. Alternatively, obese individuals showed
decreased levels of total ghrelin as a possible adaptation to the
continued negative energy balance ([43]; but see [45]). Interesting,
energy restriction also modulates CB1 expression in vagal afferent
neurons [46], suggesting that metabolic status may influence both
ghrelin and endocannabinoid systems which may interact in the
control of feeding behavior as discussed later. A detailed
understanding of the principles of ghrelin action under different
metabolic conditions and its relationship with other peptides
systems such as the ECS could be invaluable to understand the
physiological role of this hormone controlling appetite.
The role of the ECS in the regulation of food intake has been
widely studied in the past few years. However, the relative
contribution of central acting versus peripheral ECS in the
modulation of food intake and energy balance is still focus of
intense research (reviewed in [12,29]). The SR141716A-mediated
inhibition of feeding by blockade of CB1 receptors at central level
directly correlates with its anxiogenic activity. In this study we
show that the EC50 of SR141716A on food inhibition is
comparable to its EC50 for induction of anxiety. This fact is
actually a handicap for the use of CB1 antagonists in the treatment
of obesity and related disorders. According to this, to potentiate
the peripheral contribution of CB1 receptors in the control of
feeding and energy homeostasis emerges as a valuable alternative
to treat obesity, due to the devastating psychiatric side effects
found by blocking central CB1 receptors [9,12,29]. In order to test
the nature of ghrelin and ECS interaction and the contribution of
peripheral CB1 receptors in ghrelin-induced feeding, we choose an
ultra-low dose of SR141716A, which is 75 folds lower than the
EC50 for inhibition of feeding and, more importantly, for
induction of central effects such as anxiety (this paper, and [30]).
In our study we showed that an intraperitoneal ultra low-dose of
SR141716A is able to counteract the orexigenic effect of i.c.v.
ghrelin administration in free feeding animals. This result suggests
that there is a powerful cross-talk in vivo between ghrelin and ECS
in the modulation of feeding and that this interaction may be
occurring at a peripheral level, since low doses of SR141716A are
more associated with activation of peripheral sensory terminals
whereas higher doses might be related to central effects [16,35]. A
functional interaction between ghrelin and ECS has been
previously described by others showing that SR141716A (1 mg/
kg, i.p.) abolished the orexigenic effect of intra-hypothalamic
injection of ghrelin [24]. However, such interaction has been
understood as a consequence of a central cross-talk between
ghrelin and ECS in hypothalamic areas [23,24]. As presented in
Fig. 2 of this paper, the dose of 1 mg/kg of SR141716A (abscisses
0) used in the mentioned paper is a centrally acting dose that
reduce feeding effectively and induces anxiety behaviors. Our
study shows the effectiveness of a SR141716A ultra-low dose (that
neither reduce feeding by itself nor is anxiogenic) on ghrelin-
induced hyperphagia.
Figure 1. Effects of ghrelin (0.25 mg, 0.5 mg and 1.0 mg, i.c.v.) on accumulated food intake in free feeding, 24 h food-deprived
(fasted) or chronically food-restricted animals 60 min and 120 min after administration. Free-feeding animals (n = 9 in each group) had
free access to standard pellets of food; fasted rats (n = 9 in each group) were totally deprived for food during 24 h before the experiment; and chronic
food-restricted rats (n = 9 in each group) were limited daily for food intake until body weights reached 80% of free-feeding values (20–25 days). The
amount of ingested food in vehicle-injected animals was higher in the food-restricted group, following by the fasted group and free feeding rats,
respectively. Ghrelin administration induced hyperphagia at any dose tested exclusively in animals fed ad libitum. No effect of ghrelin administration
was observed in fasted or food-restricted animals. Data are means 6 SEM of accumulated food intake. Different from free feeding vehicle-injected
rats: ###P,0.001. Different from fasted vehicle-injected rats: £££P,0.001. Different from vehicle-injected rats in the same condition (free feeding):
*P,0.05. **P,0.01. ***P,0.001.
doi:10.1371/journal.pone.0060918.g001
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Additionally, we tested LH-21, a triazol derivative with poor
penetration into the central nervous system [37], in the
hyperphagia induced by ghrelin in free feeding animals. We
previously demostrated that LH-21 induces appetite reduction in
fasted rats and in free feeding animals under standard diet (and
even more efficiently under high fat diet) when treated chronically
with this peripheral CB1 antagonist [37,47]. Our results in the
present study indicate that LH-21 induces no effects in feeding by
acute administration in free feeding animals (vehicle-treated rats),
but it is highly effective blocking ghrelin-induced hyperphagia in
those animals. This latest result, together with the blockade of
ghrelin actions by subanorectic doses of SR141716A, suggests that
the interplay between ghrelin and ECS may involve peripheral
CB1 receptors. Some evidences for a peripheral influence of CB1
receptors on ghrelin actions have also been documented, giving
some insight into our results. First of all, blockade of peripheral
CB1 receptors decreases central actions of ghrelin such as ghrelin-
induced growth hormone secretion, by a CB1 receptor mediated
inhibition of hypothalamic GHRH mRNA expression that
requires intact vagal afferent fibers [48]. Secondly, SR141716A
reduce circulating plasma ghrelin levels in fed rats suggesting a
modulatory control of peripheral CB1 receptors on ghrelin
secretion by the gastrointestinal tract [49]. Thirdly, CB1 receptors
and GHS-R1a receptors are both expressed in the nodose ganglia
[7,46,50] and, precisely, intact vagal afferents neurons appears to
be required for the orexigenic effects of ghrelin [50,51,52] and the
anorectic effect of SR141716A ([35], but also see [53]). Whether
both CB1 and GHS-R1 receptors co-localize anywhere in the
ascending pathways from the periphery to the hypothalamus is still
unknown, although both ghrelin and ECS appears to modulate
the intracellular AMP-activated protein kinase in peripheral tissues
and in the hypothalamus [54,55]. It is possible that CB1 receptors
and GHS-R1a receptor co-localize en the vagus nerve (and even in
the hypothalamus) to modulate the same intracellular pathway. In
this case, ghrelin and endocannabinoids may show an orexigenic
synergic effect due to a signal amplification of one to the other in a
Figure 2. EC50 of a dose-response curve of SR141716A on food
intake and anxiety. A) effect of SR141716A (0, 0.1, 1.0 and 3.0 mg/kg,
i.p.) on responses for food; B) effect of SR141716A (0, 0.1, 1.0 and
3.0 mg/kg, i.p.) on anxiety, expressed as latency to emerge a defensive
withdrawal behaviour. The figures represent a re-analysis of the data
previously published [30]. The half maximal effective concentration
(EC50) is 2.2 mg/kg and 2.3 mg/kg for food inhibition and induction of
anxiety behavior, respectively.
doi:10.1371/journal.pone.0060918.g002
Figure 3. Pretreatment with an ultra-low dose of SR141716A or
the peripheral CB1 antagonist LH-21 on the orexigenic effect
induced by ghrelin in free feeding animals. Administration of
ghrelin (0.5 mg, i.c.v.) increased food intake in free feeding animals. A)
The subeffective dose of SR141716A (0.03 mg/kg, i.p) counteracted
ghrelin-induced orexigenic effect. As expected, the ultra-low dose of
SR141716A showed no effect on food intake in vehicle-treated animals.
B) Pretreatment with LH-21 (3 mg/kg, i.p.) counteracted the increase in
food intake induced by ghrelin and had no effect in vehicle-treated rats.
Data are means 6 SEM of 6–10 determinations per group. Different
from vehicle-injected rats: *P,0.05. ***P,0.001; different from ghrelin
treatment: #P,0.05, ##P,0.01, ###P,0.001.
doi:10.1371/journal.pone.0060918.g003
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heterodimer-like manner. Blockade of CB1 receptors may alter
this amplified signaling. Specifically, SR141716A is an inverse
agonist at CB1 receptors that presumably activates the opposite
intracellular cascade than the agonist, and thus, binding of
SR141716A to CB1 receptors may interfere with the activating
pathway of ghrelin for feeding. LH-21 is a neutral antagonist that
may then act via allosteric modulation of the heterodimer. Up to
date, CB1 receptors has been found to generate heterodimers with
G-protein coupled receptors involved in motivational behavior
and feeding, including with mu-opioid [56], dopamine D2L [57]
and orexin-1 receptors [14]. The hypothesis of heterodimerization
suggests that ghrelin may be a more potent agonist of the GHS-
R1/CB1 heteromer compared with the activation of the homomer
or the single ghrelin receptor, as it happens with orexin A, which
shows a 100-fold higher agonistic activity at OX1/CB1 hetero-
mers compared with the orexin 1-receptor homomer binding
[15,58] and, thus, administration of SR141716A causes a decrease
in the potency of orexin A in cells co-expressing both CB1 and
OX1 receptors [14]. Similarly, the GHS-R1a receptor dimeriza-
tion with other G-protein-coupled receptors involved in appetite
regulation and food reward has been described elsewhere [59].
Thus, it is feasible to think that direct/indirect interaction of both
CB1 and GHS-R1a receptors through functional heterodimeriza-
tion might contribute to the effects observed. However, this
hypothesis has to be determined. Additionally, it is known that
ghrelin prevents the CB1 receptor downregulation in the human
nodose ganglia induced by refeeding [7], indicative of the
complexity of the ECS-ghrelin interaction. Further studies are
needed to ascertain the specific nature of such interaction.
Altogether, our present results and the results exposed above
indicate that the orexigenic effect of ghrelin is not a consequence
of a simple interaction of this hormone with its receptors and other
systems within hypothalamic areas, whereas it requires intact
peripheral connections with other peptides systems, such as the
ECS, presumably in vagal afferent neurons, in order to efficiently
act on feeding behavior.
In our study we can not exclude that the ECS-ghrelin
interaction takes place directly in hypothalamic areas. Within
the hypothalamus, one of the main areas involved in energy
balance regulation, CB1 receptors are expressed in the arcuate
nuclei, the paraventricular nuclei and the lateral hypothalamic
area [60,61] and GHS-R1a receptors are expressed in paraven-
tricular, dorsomedial and ventromedial nucleus and arcuato
[8,62]. Interestingly, hypothalamic areas containing CB1 and
GSH-R1 receptors such as the arcuate nuclei are not completely
protected by the blood brain barrier because of its crucial role for
the regulation of energy homeostasis [63]. It is to note that
hypothalamic CB1 receptors are expressed in a relative low
quantity levels but its targeting shows a high efficiency functional
correlate [64]. It is possible then that the CB1 receptor interaction
with other peptide systems/hormons such as ghrelin is responsible
of such functional efficiency in the hypothalamus. Nevertherless,
although the openings in the blood brain barrier might suggest a
hypothalamic interaction the lack of activity of LH-21 or
SR151716A at the doses used in this study in the HHA axis or
inducing anxiety [30,36] weakens this hypothesis.
Taken together, our results show that ghrelin acts differently
according to the metabolic status of the animal, inducing
hyperphagia in free feeding animals but not in rats under negative
metabolic conditions. Our study also suggests that the behavioral
interaction between ghrelin and CB1 receptors in the control of
food intake may occur at the peripheral level and, therefore, we
propose that there is still a future for novel CB1 antagonists unable
to cross the blood-brain barrier to counteract the orexigenic signal
when ghrelin is overactivated.
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